Despite the technological optimism, the Capsule Endoscopy Market faces significant hurdles related to high procedure costs. While the capsules themselves have become more affordable, the cumulative cost of the hardware, software, and physician interpretation remains high compared to traditional methods. In 2025, the "hardware segment" still accounts for 55% of the market, but there is a clear trend toward lower-cost, single-use recorders to mitigate these expenses.

Looking toward 2035, the future of the market lies in Therapeutic Capsules. Research is currently underway for capsules that can not only "see" but also "do"—including taking micro-biopsies, performing targeted drug delivery, or even cauterizing small bleeds. As these multifunctional "smart pills" move through clinical trials, the market is expected to evolve from a purely diagnostic sector into a significant branch of minimally invasive surgery and targeted therapeutics.

People Also Ask:

• What are the biggest barriers to the adoption of capsule endoscopy?

• Can capsule endoscopes deliver drugs directly to a tumor?

• What is the future of "smart pills" in 2030 and beyond?